Literature DB >> 27726909

Organ Preservation Using Contact Radiotherapy for Early Rectal Cancer: Outcomes of Patients Treated at a Single Centre in the UK.

A S Dhadda1, A Martin2, S Killeen2, I A Hunter2.   

Abstract

AIMS: Contact radiotherapy for early rectal cancer uses 50 kV X-rays to treat rectal cancers under direct vision. We present data of a series of patients treated at a single centre with prospective follow-up and functional assessment.
MATERIALS AND METHODS: All patients were treated at the Queen's Centre for Oncology, Hull, UK between September 2011 and October 2015. Patients received a biopsy, magnetic resonance imaging (MRI) of the liver/pelvis, computed tomography of the chest and endorectal ultrasound. Patients were deemed to be either unfit for radical surgery or refused it due to the need for a permanent stoma. Follow-up consisted of 3 monthly flexible sigmoidoscopy and MRI of the liver/pelvis and 12 monthly computed tomography of the chest.
RESULTS: In total, 42 patients were treated with contact radiotherapy ± external beam chemo/radiotherapy without any primary surgical excision. The median age was 78 years (range 50-94 years). Local recurrence-free survival was 88%, disease-free survival was 86% and overall survival was 88% with a median follow-up of 24 months (range 5-54 months). The median time to recurrence was 12 months (range 4-14 months). The estimated 30 day surgical mortality for this cohort with radical surgery was 12%. Mortality from the contact radiotherapy procedure was 0%. Functional outcomes as investigated by the Low Anterior Resection Syndrome (LARS) score were good, with 65% having no LARS.
CONCLUSIONS: Contact radiotherapy for early rectal cancer is a safe, well-tolerated outpatient procedure, allowing organ preservation, with excellent oncological and functional outcomes. For elderly co-morbid patients with suitable rectal cancers this should be considered as a standard of care. Crown
Copyright © 2016. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Organ preservation; radiotherapy; rectal cancer

Mesh:

Year:  2016        PMID: 27726909     DOI: 10.1016/j.clon.2016.09.014

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  9 in total

1.  Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation?

Authors:  Arthur Sun Myint; Fraser McLean Smith; Simon William Gollins; Helen Wong; Christopher Rao; Karen Whitmarsh; Raj Sripadam; Paul Rooney; Michael Jeremy Hershman; Zsolt Fekete; Kate Perkins; D Mark Pritchard
Journal:  Br J Radiol       Date:  2017-11-10       Impact factor: 3.039

2.  Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence.

Authors:  Karen Benezery; Lucile Montagne; Ludovic Evesque; Renaud Schiappa; Jean-Michel Hannoun-Levi; Eric Francois; Brice Thamphya; Jean-Pierre Gerard
Journal:  Clin Transl Radiat Oncol       Date:  2020-07-06

Review 3.  A Multidisciplinary Approach for the Personalised Non-Operative Management of Elderly and Frail Rectal Cancer Patients Unable to Undergo TME Surgery.

Authors:  Stijn H J Ketelaers; Anne Jacobs; An-Sofie E Verrijssen; Jeltsje S Cnossen; Irene E G van Hellemond; Geert-Jan M Creemers; Ramon-Michel Schreuder; Harm J Scholten; Jip L Tolenaar; Johanne G Bloemen; Harm J T Rutten; Jacobus W A Burger
Journal:  Cancers (Basel)       Date:  2022-05-11       Impact factor: 6.575

Review 4.  Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer.

Authors:  Laurence Bernier; Svetlana Balyasnikova; Diana Tait; Gina Brown
Journal:  Curr Colorectal Cancer Rep       Date:  2018-03-07

5.  Organ preservation for T2-T3 rectal cancer: opportunistic or planned strategy.

Authors:  Jéan-Pierre Gérard; Nicolas Barbet; Karen Benezery
Journal:  Oncotarget       Date:  2019-05-28

6.  The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine.

Authors:  Yanli Xiong; Li Shao; Jia Liu; Qian Zhou; Chongyi Li; Maojun Liao; Lei Zhang; Xiaoyan Dai; Mengxia Li; Xin Lei
Journal:  Front Oncol       Date:  2021-11-18       Impact factor: 6.244

7.  GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer.

Authors:  Alexandra J Stewart; Evert J Van Limbergen; Jean-Pierre Gerard; Ane L Appelt; Frank Verhaegen; Maaike Berbee; Te Vuong; Ciarna Brooker; Tim Rockall; Arthur Sun Myint
Journal:  Clin Transl Radiat Oncol       Date:  2021-12-11

8.  Targeted Radiotherapy Using Contact X-ray Brachytherapy 50 kV.

Authors:  Jean-Pierre Gerard; Arthur Sun Myint; Nicolas Barbet; Catherine Dejean; Brice Thamphya; Jocelyn Gal; Lucile Montagne; Te Vuong
Journal:  Cancers (Basel)       Date:  2022-03-03       Impact factor: 6.639

9.  Contact X-ray Brachytherapy for Older or Inoperable Rectal Cancer Patients: Short-Term Oncological and Functional Follow-Up.

Authors:  Petra A Custers; Barbara M Geubels; Inge L Huibregtse; Femke P Peters; Ellen G Engelhardt; Geerard L Beets; Corrie A M Marijnen; Monique E van Leerdam; Baukelien van Triest
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.